SCHEMBL3760229

SCHEMBL3760229

[c]1nccc(N2CCCCC2)c1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
ALDH1A1 P00352 5/20 0.40
KEAP1 Q14145 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.39
HPGD P15428 3/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
HSD17B10 Q99714 3/20 0.39
MAPT P10636 2/20 0.39
TSHR P16473 2/20 0.39
AR P10275 1/20 0.39
RECQL P46063 1/20 0.39
GAA P10253 1/20 0.39
TP53 P04637 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
LMNA P02545 3/20 0.38
NCF1 P14598 2/20 0.38
ACP1 P24666 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3756163 0.98 KDM4E (0.41) KDM4EL3MBTL1ALDH1A1KEAP1SMN1; SMN2
SCHEMBL3762327 0.95 KDM4E (0.38) KDM4EL3MBTL1ALDH1A1KEAP1SMN1; SMN2
SCHEMBL3763677 0.84 PDE4A (0.46) KDM4EALDH1A1SMN1; SMN2HPGDNPC1
SCHEMBL3760252 0.84 HTR6 (0.51) NCF1
SCHEMBL3754790 0.77 NPY5R (0.43) KDM4EL3MBTL1ALDH1A1KEAP1SMN1; SMN2
SCHEMBL6850968 0.77 KDM4E (0.44) KDM4EL3MBTL1ALDH1A1SMN1; SMN2NPC1
SCHEMBL2353322 0.76 ROCK1 (0.49) KDM4EL3MBTL1ALDH1A1KEAP1HPGD
SCHEMBL3751377 0.75 NPY5R (0.41) KDM4EL3MBTL1ALDH1A1KEAP1SMN1; SMN2
SCHEMBL15415550 0.74 CHKA (0.38) L3MBTL1ALDH1A1KEAP1HPGDHSD17B10
SCHEMBL4235717 0.74 CHKA (0.38) L3MBTL1ALDH1A1KEAP1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA KDM4E 1014/4885L3MBTL1 1887/4885ALDH1A1 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.